novo
`nordisk
`history
`
`1970
`
`1990
`
`1980
`
`2000
`
`changing
`diabetes·
`
`~ nova nordisk®
`
`Sanofi Exhibit 2137.001
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`Preface
`
`Behind the Novo Nordisk we know today
`lies an exciting story that goes back more
`than 85 years. It began with two small
`Danish firms established in Copenhagen
`in the 1920s - Nordisk lnsulinlaboratorium
`
`and Novo Terapeutisk Laboratorium*
`- who under modest circumstances
`began manufacturing a revolutionary
`new medicine, insulin, that had just been
`discovered by two Canadian scientists.
`
`Competing intensely with one another, the
`compan ies developed into two of the best
`in their field. When at last they decided
`to merge in 1989, they created one of the
`world's largest biotechnology groups - a
`group that has been expanding rapidly ever
`since.
`
`This booklet tells in words and pictures
`of the many events that are the story of
`Novo Nordisk - a fascinating tale of one
`
`pioneering product after another, developed
`through the inspired thinking of talented
`and ambitious people.
`
`We hope you will enjoy the story!
`
`Novo Nordisk is a global
`healthcare company with more
`than 85 years of innovation
`and leadership in diabetes care.
`The company also has leading
`positions within haemophilia
`care, growth hormone therapy
`and hormone replacement
`therapy. Headquartered in
`Denmark, Novo Nordisk employs
`more than 30,000 employees
`in 76 countries, and markets its
`products in 179 countries. Novo
`Nordisk's B shares are listed on
`NASDAQ OMX Copenhagen
`(Novo-8). Its ADRs are listed on
`the New York Stock Exchange
`(NVO). For more information,
`visit novonordisk.com.
`
`* Both Nordisk lnsulinlaboratorium and Novo Terapeutisk Laboratorium changed their names several times over the
`years. To make thing s easier for our readers, we refer to the two compa nies as Nordisk and Novo respectively.
`
`NOVO NORDISK HISTORY
`
`Sanofi Exhibit 2137.002
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`NOVO NORDISK HISTORY
`
`5
`
`Sanofi Exhibit 2137.006
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`
`
`Sanofi Exhibit 2137 .008
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`

`

`

`

`

`

`

`

`
`
`Sanofi Exhibit 2137.016
`Sanofi Exhibit 2137.016
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`NOVO NORDISK HISTORY
`
`19
`
`Sanofi Exhibit 2137.020
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`. 95:...1‘wm93
`"-'=‘
`'
`K5113 WEE
`""535
`W---i*i QMW3-
`---- .- Kmmuogo - ’ IW-
`----- natal”. :-3 ‘
`---I Lamont». ---- "
`-l- mum ---
`J I. Novo B
`'
`.- -r’§"
`“*Poulsenaflagoczy. --/
`I. HRasI'rL&Co.stan - ._
`'l.HRm&Co.praf - ‘
`u C.:Scl'lousFab..dn./_--I-.
`C.Schoquab.B- -- -...
`—-- Warm -- ..
`-. 4251-. Svendb. VaarnA. .---
`--- ;
`Svendb VaerrtB ---
`---- ThorsKemiske -
`Weilb. 8: Cohn
`.1
`" Jens Villadsen
`-
`'
`
`
`
`'
`
`Sanofi Exhibit 2137.022
`Sanofi Exhibit 2137.022
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`IPR2018-01676
`
`.
`
`'Aalb.PorLr
`‘Aalb.Port.
`Aall
`
`.. "5,1. Aarhu:
`
`-<’
`
`9,,” '
`I.
`
`"
`
`"
`
`

`

`

`

`NOVO NORDISK HISTORY
`
`23
`
`Sanofi Exhibit 2137.024
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`NOVO NORDISK HISTORY
`
`27
`
`Sanofi Exhibit 2137.028
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`
`
`Sanofi E~hibit 2137.030
`Sanofi Exhibit 2137.030
`ylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`IPR2018-01676
`
`

`

`

`

`NOVO NORDISK HISTORY
`
`31
`
`Sanofi Exhibit 2137.032
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`
`
`Familieplanlaegning med Delpregnin
`—- det orale antikonceptionsmiddel
`
`Sanofi Exhibit 2137.034
`Sanofi Exhibit 2137.034
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`lPR2018-01676
`
`

`

`

`

`
`
`Sanofi Exhibit 2137.036
`Sanofi Exhibit 2137.036
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`lPR2018-01676
`
`

`

`

`

`NOVO NORDISK HISTORY
`
`37
`
`Sanofi Exhibit 2137.038
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`
`
`Sanofi Exhibit 2137.040
`Sanofi Exhibit 2137.040
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`lPR2018-01676
`
`

`

`

`

`
`
`Sanofi Exhibit 2137.042
`Sanofi Exhibit 2137.042
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`

`

`

`

`

`

`----- . Ii~
`_ __ _ - - - -- -I- • [ _ll
`_ ---~-t-_ . .,.1·"""1•~ : : I i
`\
`. :.~·1~~t;:~1. _ .
`l f.. •.!j
`- . . . -,i•111fti
`-----~~, .. _ :.1-
`,·-•t: :II . Wr ~
`. !E~ ~-. ~! ~ __ _ t
`I I\ _\ t ', ~~ ~ I
`Ill
`
`I
`
`.
`
`In 1997, a new plant in Koriyama, Japan,
`was inaugurated.
`
`2 In 2000, Novo Nordisk inaugurated a 16,000
`m2 facility in Hillerod, Denmark, for the
`production of the Novolet® prefilled insulin
`pen. Two years later, the foundation stone
`was laid for a new NovoSeven® factory.
`
`3 In 2007, Novo Nordisk's insulin production
`plant in Montes Claros, Brazil, was expanded,
`and production at the site increased fivefold.
`
`4 The groundbreaking ceremony for Novo
`Nordisk's new plant in Tianjin, China, took
`place on 7 November 2008.
`
`48
`
`NOVO NORDISK HISTORY
`
`Business strategy
`
`In 1994, Novo Nordisk implemented a new
`business strategy to ensure progress in a
`
`rapidly changing and ever more competitive
`world. Focus was on the two core business
`areas, Health Care and Enzyme Business,
`
`increased performance in turnover and
`
`market share in the years approaching the
`new millennium. By 2001, sales in the five(cid:173)
`
`year period up to that year had doubled .
`
`while other areas such as Ferrosan (dietary
`supplements and other over-the-counter
`
`Markets grew in Europe, the US and Japan.
`The same trends held in other, less well(cid:173)
`
`products) and Plant Protection (biological
`
`plant protection) were divested.
`
`The plan for Health Care was to develop
`
`the diabetes care business to encompass
`a broader portfolio of products and
`services that offer patients and healthcare
`
`professionals better treatment solutions.
`At the same time, efforts were made to
`reinforce growth hormone therapy and
`
`hormone replacement therapy (H RT) with
`new indications and introduction into new
`markets.
`
`The best in its markets
`
`In 1996, this focused business strategy
`was followed up by a reorganisation of
`the staff and service functions, and the
`
`management strategy was adapted a year
`later. Procedures and activities that did not
`add substantial value to Novo Nordisk were
`
`dropped, and the resources thus liberated
`were used for development and marketing.
`This change process produced results and
`
`helped fuel Novo Nordisk's significantly
`
`developed markets in Eastern Europe, Asia
`and Latin America. As turnover increased,
`the company needed increasingly larger
`
`and more modern production facilities,
`as well as more employees . Thus Novo
`Nordisk embarked in 2001 on the biggest
`
`investment programme in the history of the
`company.
`
`Increased globalisation
`The company became increasingly
`
`globalised in the following years. In the
`first decade of the new millennium, Novo
`Nordisk invested in large new production
`
`plants in Brazil and China and a sizeable
`expansion of the organisation outside
`Denmark. In 2007, for the first time, more
`than half of Novo Nordisk's workforce was
`
`employed outside Danish borders. Strong
`focus on the company's core competences
`
`combined with willingness to invest in
`markets with long-term growth potential
`are cornerstones of Novo Nordisk's future
`
`business strategy.
`
`Sanofi Exhibit 2137.049
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`NOVO NORDISK HISTORY
`
`49
`
`Sanofi Exhibit 2137.050
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`

`

`

`

`

`

`

`

`NOVO NORDISK HISTORY
`
`57
`
`Sanofi Exhibit 2137.058
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`

`

`

`

`NOVO NORDISK
`
` NOVO NORDISK
`
`Sanofi Exhibit 2137.062
`Sanofi Exhibit 2137.062
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`lPR2018-01676
`
`

`

`0
`
`changing
`diabetes®
`
`Novo Nordisk today
`and tomorrow
`
`In 2005, Novo Nordisk launched the
`corporate brand concept Changing
`Diabetes®. With this promise of change
`
`Novo Nordisk recognises that as a world
`leader in diabetes care, the company has
`
`the responsibility to make a difference by
`both offering innovative treatments and
`driving initiatives to create real change in
`
`celebrate the UN adoption of a Resolution
`on diabetes making World Diabetes Day an
`
`official UN day.
`
`A further change initiative is the series of
`Changing Diabetes® Leadership Forums
`
`where experts aim to get diabetes on the
`global political agenda. The first forum
`
`the lives of people with diabetes and at risk
`of diabetes . These initiatives target a wide
`variety of stakeholders including patients,
`
`was held in 2007; at this gathering, the
`development of a Changing Diabetes®
`
`Barometer to measure the progress of
`
`healthcare professionals and policy-makers.
`
`diabetes care around the world was
`announced. The Changing Diabetes®
`
`Among these initiatives is DAWN '" (Diabetes
`
`Barometer website was launched in 2009.
`
`Novo Nordisk's corporate brand concept,
`Changing Diabetes®, is a concerted effort to
`create positive changes in the lives of people
`with diabetes around the world.
`
`2 In 2006, the Novo Nordisk Changing
`Diabetes® Bus embarked on a world tour
`with information about diabetes and its
`prevention.
`
`3 Punithevel Thankikachalam lives in India
`and has type 2 diabetes.
`
`4 Novo Nordisk participated in the Unite for
`Diabetes campaign, which in 2006 succeeded
`in making World Diabetes Day a UN-recognised
`day.
`
`5 Zandile Signoria Mzayifani from South Africa
`with the words she expressed about living
`with type 2 diabetes.
`
`62
`
`NOVO NORDISK HISTORY
`
`Attitudes, Wishes and Needs), launched
`
`by Novo Nordisk in 2001 to discover the
`psychosocial needs of people with diabetes.
`DAWN'" was established prior to the
`concept of Changing Diabetes® but has
`
`since been refined.
`
`In 2006, a worldwide campaign was
`initiated by the International Diabetes
`
`Federation to gain UN recognition of World
`Diabetes Day 14 November. That inspired
`Novo Nordisk to create the Changing
`Diabetes® Bus, a mobile awareness-raising
`and diabetes-screening unit. It embarked
`
`on its worldwide journey in 2006 and was
`
`prominent in the IDF campaign, which was
`a success . In December 2006, the Changing
`Diabetes® Bus rolled into New York to
`
`With the arrival of the new Novo Nordisk
`Way in 2011, the Changing Diabetes®
`
`concept was strengthened to deeper reflect
`the company's commitment to patients.
`
`Building on the past - looking to the future
`
`Novo Nordisk will continue to develop
`treatments and initiatives to benefit people
`
`with diabetes . In this way, the company will
`continue to build on the legacy left by the
`founders of Novo Nordisk and do whatever
`
`it takes to change diabetes. Our history tells
`us it can be done.
`
`Sanofi Exhibit 2137.063
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`

`

`Milestones in Novo Nordisk 1s history
`
`Novo Nord isk was created in 1989 through a merger between two
`Danish companies- Novo lndustri A/Sand Nordisk Gentofte A/S.
`
`1923
`
`Nordisk lnsulinlaboratorium founded.
`
`1925
`
`Novo Terapeutisk Laboratorium founded.
`
`1926
`
`Nordisk establishes the Nordisk Insulin Foundation with the
`ob1ect of supporting physiological and endocrinological
`research and people with diabetes in Scandinavia.
`
`1932
`
`Nordisk founds the Steno Memorial Hospital.
`
`1938
`
`Novo founds Hvid0re Diabetes Sanatorium.
`
`1946
`
`Nordisk develops isophane insulin (NPH), a neutral insulin
`with prolonged action.
`
`1947
`
`1951
`
`1953
`
`1973
`
`1973
`
`1974
`
`1981
`
`1982
`
`Penicillin Novo is launched- Novo's first product to be
`manufactured through fermentation.
`
`Novo establishes the Novo Foundation with the ob1ect of
`supporting scientific, social and humanitarian causes and to
`provide the best possible protection for the company.
`
`Novo launches Lente® - a long-acting insulin-zinc
`suspension.
`
`Nordisk markets Nanormon ® growth hormone for the
`treatment of growth hormone insufficiency. The growth
`hormone is extracted from human pituitary glands.
`
`Novo introduces Monocomponent (MC) insulin -the purest
`insulin available.
`
`Novo's B shares are quoted on the Copenhagen Stock
`Exchange.
`
`Novo becomes the first company in Scandinavia to be
`quoted on the New York Stock Exchange.
`
`launched-the world's
`Human Monocomponent insulin
`first insulin preparation identical to human insulin. It is
`extracted from the pancreases of pigs and converted to
`human insulin.
`
`1985
`
`NovoPen® is launched - an in1ection system similar in
`appearance to a fountain pen, with replaceable insulin
`cartridges.
`
`1987
`
`Novo starts production of human insulin with the help of
`genetically engineered yeast cells.
`
`1988
`
`1988
`
`1989
`
`Novo markets Vagifem®-the first vaginal tablet for atrophic
`vaginitis
`
`Nordisk markets Norditropin ® genetically engineered human
`growth hormone.
`
`Nordisk lnsulinlaboratorium, the Nordisk Insulin Foundation
`and the Novo Foundation merge to become the Novo
`Nordisk Foundation. The ob1ects are to provide a stable basis
`for the Novo Group companies' operations and to support
`scientific causes.
`
`1989
`
`Novo lndustri A/Sand Nordisk Gentofte A/S merge to
`become Novo Nordisk A/S - the world's leading producer of
`insulin.
`
`1989
`
`Novolet® is marketed-the world's first prefilled insulin
`syringe.
`
`1991
`
`1992
`
`Novo Nordisk Joins the environmental charter of the
`International Chamber of Commerce (ICC).
`
`The Steno Memorial Hospital and Hvid0re Hospital merge to
`form the Steno Diabetes Center.
`
`1994
`
`Novo Nordisk is the first company in Denmark- and one of
`the first in the world-to publish an environmental report.
`
`1996
`
`1998
`
`1998
`
`NovoSeven ® is launched-for the treatment of haemophilia
`patients with inhibitor reaction.
`
`NovoNorm ® (Prandin ® in the US) - a new oral treatment for
`type 2 diabetes - is launched in the US and a number of
`European countries.
`
`Activelle® (Activella® in the US) is introduced - the first
`low-dose continuous combined oral HRT for
`postmenopausal women.
`
`1999
`
`Novo Nordisk publishes its first social report.
`
`64
`
`NOVO NORDISK HISTORY
`
`Sanofi Exhibit 2137.065
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`1999
`
`1999
`
`2000
`
`2001
`
`2001
`
`2001
`
`2002
`
`NovoRapid® (Novolog® in the US) - the company's first
`modern insulin, a rapid-acting insulin analogue - is
`marketed. Modern insulins are designed to better mimic the
`normal insulin response to changes in blood sugar levels.
`
`2006
`
`Novo Nordisk signs an agreement with WWF that commits
`the company to reduce its carbon emissions by 10% by 2014
`compared with 2004. Novo Nordisk is the 10th company in
`the world to Join the WWF Climate Savers initiative.
`
`Norditropin® SimpleXx® is launched-the world's first liquid
`growth hormone in a dedicated pen system.
`
`split into three separate companies
`Novo Nordisk
`operating under the umbrella of the Novo Group:
`Novo Nordisk A/S, Novozymes A/Sand Novo A/S.
`
`lnnolet® is launched-the first insulin delivery system
`specially designed to suit the needs of insulin users with
`poor eyesight and reduced dexterity.
`
`Novo Nordisk establishes the World Diabetes Foundation
`with the purpose of improving diabetes care in developing
`countries.
`
`NovoRapid® FlexPen® is marketed. FlexPen® is a new
`prefilled pen, designed for easy and discreet use.
`
`Novo Nordisk signs the United Nations Global Compact,
`a platform for promoting good corporate principles and
`learning experiences in the areas of human rights, labour,
`environment and anti-corruption.
`
`2007
`
`Active Ila ® 0.5 mg/0.1 mg is launched in the US -the
`first ultra-low-dose oral HRT for women with
`menopausal symptoms.
`
`2007
`
`In Montes Claros, Brazil, Novo Nordisk inaugurates its
`largest insulin production facility outside of Denmark.
`
`2009
`
`2010
`
`2010
`
`Victoza ®-human Glucagon-Like Peptide-1 (GLP-1)
`analogue for once-daily treatment of adults with type 2
`diabetes- is launched in Europe.
`
`Vagifem ® 10 mcg is launched in the US and Europe. The
`medication provides the lowest dose of vaginal oestrogen
`commercially available for women with vaginal atrophy.
`
`Novo Nordisk launches NovoPen Echo®, a new insulin
`pen developed especially for children. Initially launched in
`Denmark, the pen includes a memory function and half-unit
`dosing increments.
`
`2002
`
`NovoMix® 30 is introduced- a dual release modern insulin.
`
`2003
`
`Norditropin NordiFlex® is launched - the world's first
`prefilled growth hormone pen.
`
`2004
`
`Levemir® is launched- a long-acting modern insulin.
`
`2004
`
`2005
`
`Novo Nordisk's Articles of Association are amended to
`specify that the company will "strive to conduct its activities
`in a financially, environmentally and socially responsible
`way
`
`The Novo Nordisk Haemophilia Foundation is set up in
`response to the significant need to improve haemophilia
`treatment in the developing world, underlining the
`company's social responsibility within haemophilia care.
`
`Not all products have been introduced worldwide. Trade names may
`vary from country to country.
`
`© Novo Nordisk A/S 2010
`
`3rd revised edition, 2011
`
`NOVO NORDISK HISTORY
`
`65
`
`Sanofi Exhibit 2137.066
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`ISBN: 978—87-993835-1—1
`ISBN 978-87-993835-1-1
`
`Sanofi Exhibit 2137.067
`Sanofi Exhibit 2137.067
`Mylan v. Sanofi
`Mylan v. Sanofi
`IPR2018-01676
`lPR2018-01676
`
`

`

`1930
`
`1950
`
`1940
`
`1960
`
`Novo Nordisk A/S
`Novo Alie
`2880 Bagsvcerd
`
`Denmark
`
`novonordisk.com
`
`ISBN 978-87-99383 5-1-1
`
`Sanofi Exhibit 2137.068
`Mylan v. Sanofi
`IPR2018-01676
`
`